PARP1 and neoplasm: Inhibition with TG101209 and AZ960 reduces proliferation in tumorigenic SP/CD44+ cells (603), while momelotinib suppresses tumor growth by targeting JAK2 and downregulating PARP1 through the IFNGR-JAK2-STAT1-PARP1 axis (604).